Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > “Low dose docetaxel”

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Oct 11, 2022 5:33pm

146 Views

Post# 35018256

RE:RE:RE:RE:“Low dose docetaxel”

I dont know any of them but I am quite certain that oncology analysts of major brokerage houses have consulted with their in house experts and obviously the enthusiasm has been close to zero

The incentive to be the first or amongst the first to take a position in a disruptive technology with the potential for once in a lifetime return is the dream of every analyst...Yet nobody amongst the analysts have made a buy recmmendation based on TH 1902....Greed is part of probably close to 100% of brokerage houses ....Risk taking is part of their DNA but they have so far elected not to get involved
They are noy looking for certainty but obviously they are not seeing enough meat on the bone at this time ....If and when they do the SP will react way before clnical results